Related Experiment Video

Updated: Jul 7, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors

T Inoue1, I Hirata, M Murano

  • 1Second Department of Internal Medicine, Osaka Medical College, 2-7 Daigakumachi, Takatsuki city, Osaka, 569-8686, Japan. ino-taku@sa2.so-net.ne.jp

Inflammopharmacology
|February 8, 2008
PubMed

Insights

Nimesulide, a selective COX-2 inhibitor, demonstrated preventive effects against colorectal neoplasia in a mouse model of ulcerative colitis. It significantly suppressed dysplasia and cancer during the remission phase of carcinogenesis.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Cyclooxygenase-2 (COX-2) plays a role in suppressing sporadic colorectal cancer.
  • The impact of selective COX-2 inhibitors on ulcerative colitis (UC)-associated neoplasia remains unclear.

Purpose of the Study:

  • To investigate the effect of a selective COX-2 inhibitor, nimesulide (NIM), on colorectal carcinogenesis in a murine model of UC.

Main Methods:

  • Chronic colitis was induced in mice using dextran sulfate sodium (DSS) over four cycles.
  • Mice received NIM during different phases: throughout the study, during DSS administration, or during the remission phase post-DSS.
  • Neoplasia development was assessed 120 days after the final DSS cycle.

Main Results:

  • Nimesulide significantly suppressed the occurrence of dysplasia and/or cancer in mice treated during the remission phase (Group D).
  • NIM demonstrated inhibitory effects on both dysplasia and cancer in DSS-treated mice.

Conclusions:

  • Nimesulide exhibits preventive effects on colorectal carcinogenesis, particularly during the remission phase of UC-associated neoplasia.
  • Selective COX-2 inhibition may be a viable strategy for preventing neoplasia in the context of ulcerative colitis.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)12:37

Modeling Colitis-Associated Cancer with Azoxymethane (AOM) and Dextran Sulfate Sodium (DSS)

Published on: September 11, 2012

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...